JPRN-UMIN000038663招募中未知
Evaluation of the efficacy and safety of sildosin 2 mg versus sildosin 4 mg in premature ejaculation: a prospective study - alpha blockers and premature ejaculation
AlAzhar university0 个研究点目标入组 100 人开始时间: 2019年11月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30years-old 至 45years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •All males who suffer from ED or prostatitis or receive medications that affect ejaculatory function
研究者
相似试验
进行中（未招募）
不适用
EVALUATION OF THE EFFICACY AND SAFETY OF SILODOSIN vs. TAMSULOSIN AND PLACEBO IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA. MULTICENTRE, RANDOMISED, DOUBLE-BLIND, CONTROLLED TRIAL WITH AN OPTIONAL LONG-TERM OPEN-LABEL EXTENSION PHASE - NDEUCTR2005-005665-11-ITRECORDATI1,400
进行中（未招募）
1 期
Evaluation Of The Efficacy And Safety Of Silodosin Vs. Tamsulosin And Placebo In The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia. Multicentre, Randomised, Double-Blind, Controlled Trial With An Optional Long-Term Open-Label Extension PhaseBenign prostatic hyperplasia (BPH) is a non malignant enlargement of the prostate due to cellular hyperplasia of both glandular and stromal elements. As the prostate increases in size it may exert pressure on the lumen of the prostatic urethra, resulting in a gradual obstruction to urine flow.MedDRA version: 8.1 Level: LLT Classification code 10004446EUCTR2005-005665-11-GBRecordati S.p.A1,400
进行中（未招募）
不适用
Evaluation Of The Efficacy And Safety Of Silodosin Vs. Tamsulosin And Placebo In The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia. Multicentre, Randomised, Double-Blind, Controlled Trial With An Optional Long-Term Open-Label Extension PhaseEUCTR2005-005665-11-FIRecordati S.p.A1,400
进行中（未招募）
1 期
Evaluation Of The Efficacy And Safety Of Silodosin Vs. Tamsulosin And Placebo In The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia. Multicentre, Randomised, Double-Blind, Controlled Trial With An Optional Long-Term Open-Label Extension PhaseBenign prostatic hyperplasia (BPH) is a non malignant enlargement of the prostate due to cellular hyperplasia of both glandular and stromal elements. As the prostate increases in size it may exert pressure on the lumen of the prostatic urethra, resulting in a gradual obstruction to urine flow.MedDRA version: 8.1Level: LLTClassification code 10004446EUCTR2005-005665-11-ESRecordati S.p.A1,400
进行中（未招募）
不适用
EFFECTIVENESS AND SAFETY OF SILODOSIN IN THE TREATMENT OF LUTS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA: A EUROPEAN PHASE IV CLINICAL STUDY - SiREEUCTR2011-000045-20-ITRECORDATI1,000